Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog



Aurora Kinase inhibitors

01 Jul 05

Cell cycle inhibitors represent a key approach to the treatment of cancer. Therapeutic agents have traditionally targeted early stages of the cell cycle (ie the G1/S phase checkpoint or the S phase) or mitotic spindle formation as exemplified by the alkaloids. Recently a new approach to cell cycle regulation has emerged with the identification of the Aurora kinase family. This report evaluates this exciting area of drug discovery

TherapeuticAdvance-June 2005

29 Jun 05

Welcome to the June edition of TherapeuticAdvances, LeadDiscovery's free newsletter for the drug development sector. Read on for editorial comment on selected studies recently featured on DailyUpdates our regular bulletin of breaking journal articles and drug development news

Chronic viral hepatitis: B is for billions

28 Jun 05

Despite recent advances in the treatment and management of hepatitis B, the market is still relatively immature, with several key unmet needs. Current pipeline products are expected to account for 89% of total market sales by 2015, however other developmental antivirals are also expected to contribute significantly to future market growth, potentially resulting in new treatment paradigms.

Novartis compound paves way for potent COPD combinations

17 Jun 05

Novartis has unveiled promising Phase II data for its once-daily bronchodilator, indacaterol (QAB-149). With a long duration of action, rapid onset of action and clean side effects profile, the drug could provide a new standard for bronchodilator therapy in patients with asthma and chronic obstructive pulmonary disease (COPD).


17 Jun 05

The ancient Egyptians thought that diabetes was due to an ‘imbalance of the four bodily elements’ and that the best treatment to give these patients was a mixture of ground earth, water, wheat and lead. Thankfully, things have improved a little since then! In fact, the most important advance in diabetes management occurred in 1921 when the young surgeon Frederick Banting and the even younger medical student, Charles Best, first isolated insulin.
CSF Medical

How are your customers directed to work with you?

16 Jun 05

Don’t take it personally if customers seem more paranoid in your presence these days. There have been a number of directives governing their interaction with the pharmaceutical industry. This has made many of them uneasy and indeed uncertain about what they can do and say in the presence of a medical sales person.
Miriam George

Cash injection could ease UK stroke burden

10 Jun 05

Stroke is the third leading cause of death in adults in developed countries. It can also leave survivors severely disabled and dependent on long-term care, placing an enormous financial burden on national healthcare systems. This burden is likely to further increase as the incidence of stroke increases concurrent with the aging population.


08 Jun 05

Fewer than 10% of people state that they have never had a headache.1 A recent UK survey identified 7.6% of males and 18.3% of females with migraine within the preceding year.2 Prevalence of migraine was shown to vary with age, rising through early adult life and declining in the late 40s and early 50s. Migraineurs reported at least one migraine attack per month on average, and most experienced interference with daily activities in at least 50% of their attacks.
CSF Medical Communications

The Royal Borough’s Best Business Revealed

08 Jun 05

The winner of the coveted title of Business of the Year at the 2005 Royal Borough Business Excellence Awards was crowned last week at the awards evening. The team at Pharmalink Consulting was congratulated by David Demolder, of award sponsor Ascot Racecourse for the overall quality of their business.
Lisa Drew

HIV pipeline offers optimistic outlook over the longer term

03 Jun 05

Of the 27 drugs currently in the HIV clinical development pipeline, the majority are in either Phase II trials or earlier. While the pipeline is considered strong, it is unlikely that any major treatment advances will be made before 2009/10. In fact, two of the more advanced drugs in terms of development - tipranavir and capravine - are likely to be used merely as 'holding drugs'.

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.